Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose cabozantinib with escalation in second-line advanced hepatocellular carcinoma
2020-000775-20Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Treatment discontinuation rate due to treatment-related adverse events. Started Apr 2020; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2020-000775-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000775-20.